Haploidentical transplantation and posttransplant cyclophosphamide for treating aplastic anemia patients: a report from the EBMT Severe Aplastic Anemia Working Party

被引：0

作者：

Pedro H. Prata

Dirk-Jan Eikema

Boris Afansyev

Paul Bosman

Frans Smiers

José L. Diez-Martin

Celso Arrais-Rodrigues

Yener Koc

Xavier Poiré

Anne Sirvent

Nicolaus Kröger

Fulvio Porta

Wolfgang Holter

Adrian Bloor

Charlotte Jubert

Arnold Ganser

Alina Tanase

Anne-Lise Ménard

Pietro Pioltelli

José A. Pérez-Simón

Aloysius Ho

Mahmoud Aljurf

Nigel Russell

Helene Labussiere-Wallet

Tessa Kerre

Vanderson Rocha

Gérard Socié

Antonio Risitano

Carlo Dufour

Régis Peffault de Latour

机构：

[1] Saint-Louis Hospital,Hematology

[2] EBMT Statistical Unit,Transplantation Department

[3] First State Pavlov Medical University,Departamento de Medicina, Gregorio Maranon G.U. Hospital, Instituto de Investigación Sanitaria Gregorio Marañón

[4] EBMT Data Office,undefined

[5] Leiden University Hospital,undefined

[6] Universidad Complutense,undefined

[7] Sírio-Libanês Hospital,undefined

[8] Medical Park Hospitals,undefined

[9] Clinique Universitaire St. Luc,undefined

[10] CHU Lapeyronie,undefined

[11] University Hospital Eppendorf,undefined

[12] Ospedale dei Bambini Spedali Civili,undefined

[13] St. Anna Kinderspital,undefined

[14] Christie NHS Trust Hospital,undefined

[15] Groupe Hospitalier Pellegrin-Enfants,undefined

[16] Hannover Medical School,undefined

[17] Fundeni Clinical Institute,undefined

[18] Centre Henri Becquerel,undefined

[19] Ospedale San Gerardo,undefined

[20] Hospital Universitario Virgen del Rocio,undefined

[21] Singapore General Hospital,undefined

[22] King Faisal Specialist Hospital & Research Centre,undefined

[23] Nottingham University,undefined

[24] Centre Hospitalier Lyon Sud,undefined

[25] Ghent University Hospital,undefined

[26] Université de Paris,undefined

[27] Federico II University of Naples,undefined

[28] Giannina Gaslini Children’s Hospital,undefined

来源：

Bone Marrow Transplantation | 2020年 / 55卷

关键词：

D O I：

暂无

中图分类号：

学科分类号：

摘要：

In the absence of an HLA-matched donor, the best treatment for acquired aplastic anemia patients refractory to immunosuppression is unclear. We collected and analyzed data from all acquired aplastic anemia patients who underwent a haploidentical transplantation with posttransplant cyclophosphamide in Europe from 2011 to 2017 (n = 33). The cumulative incidence of neutrophil engraftment was 67% (CI95%: 51–83%) at D +28 and was unaffected by age group, stem cell source, ATG use, or Baltimore conditioning regimen. The cumulative incidence of grades II–III acute GvHD was 23% at D +100, and limited chronic GvHD was 10% (0–20) at 2 years, without cases of grade IV acute or extensive chronic GvHD. Two-year overall survival was 78% (64–93), and 2-year graft-versus-host disease-free survival was 63% (46–81). In univariate analysis, the 2-year OS was higher among patients who received the Baltimore conditioning regimen (93% (81–100) versus 64% (41–87), p = 0.03), whereas age group, stem cell source, and ATG use had no effect. Our results using unmanipulated haploidentical transplantation and posttransplant cyclophosphamide for treating refractory AA patients are encouraging, but warrant confirmation in a prospective study with a larger number of patients and longer follow-up.

引用

页码：1050 / 1058

页数：8

共 220 条

[11]

Calvo KR(2008)HLA-haploidentical bone marrow transplantation for hematologic malignancies using nonmyeloablative conditioning and high-dose, posttransplantation cyclophosphamide Biol Blood Marrow Transpl 14 641-50

[12]

Desmond R(2018)Refined graft-versus-host disease/relapse-free survival in transplant from HLA-identical related or unrelated donors in acute myeloid leukemia Bone Marrow Transpl 53 1295-303

[13]

Tang Y(2013)Suggestions on the use of statistical methodologies in studies of the European Group for Blood and Marrow Transplantation Bone Marrow Transpl 48 S1-37

[14]

Dumitriu B(2011)Decreased infection-related mortality and improved survival in severe aplastic anemia in the past two decades Clin Infect Dis 52 726-35

[15]

Townsley DM(2016)Unrelated alternative donor transplantation for severe acquired aplastic anemia: a study from the french society of bone marrow transplantation and cell therapies and the EBMT severe aplastic anemia working party Haematologica. 101 884-90

[16]

Olnes MJ(2007)Unrelated stem cell transplantation for severe acquired aplastic anemia: improved outcome in the era of high-resolution HLA matching between donor and recipient Haematologica. 92 589-96

[17]

Broder K(1993)Malignant tumors occurring after treatment of aplastic anemia. European Bone Marrow Transplantation-Severe Aplastic Anaemia Working Party N. Engl J Med 329 1152-7

[18]

Scheinberg P(2011)Influence of nucleated cell dose on overall survival of unrelated cord blood transplantation for patients with severe acquired aplastic anemia: a study by eurocord and the aplastic anemia working party of the european group for blood and marrow transplant Biol Blood Marrow Transpl 17 78-85

[19]

Desmond R(2018)Unrelated cord blood transplantation in patients with idiopathic refractory severe aplastic anemia: a nationwide phase 2 study Blood. 132 750-4

[20]

Bevans M(2012)Evaluation of HLA matching requirements in unrelated hematopoietic stem cell transplantation for nonmalignant disorders Blood. 120 2918-24

← 1 2 3 4 5 6 7 8 9 10 →